Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL7902663 | 1.00 | KIF11 (0.45) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| Glutamic Acid SCHEMBL4697460 | 1.00 | KIF11 (0.45) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| Glutamic Acid SCHEMBL5196110 | 0.91 | SLC1A3 (0.53) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| D-Glutamate SCHEMBL5196106 | 0.91 | SLC1A3 (0.53) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| Glutamic Acid SCHEMBL1873097 | 0.91 | SLC1A3 (0.53) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| Aspartic Acid SCHEMBL9856999 | 0.88 | CYP2D6 (0.45) | KIF11ALDH1A1GRIK1CYP2D6MAPK1 | |
| Aspartic Acid SCHEMBL8932898 | 0.88 | CYP2D6 (0.45) | KIF11ALDH1A1GRIK1CYP2D6MAPK1 | |
| D-Glutamate SCHEMBL28273054 | 0.84 | GRM8 (0.58) | KIF11ALDH1A1GRIK1GRM8GRM6 | |
| Glutamic Acid SCHEMBL8648352 | 0.83 | GRIK1 (0.64) | KIF11GRIK1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL7782949 | 0.83 | GRIK1 (0.64) | KIF11GRIK1GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609721-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GEORGETOWN UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-7381745-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1177200-B1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | UNIV GEORGETOWN (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040002478-A1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | NIH - DEITR | 2004-01-01 | — | — | US | disclosed |
| US-6528499-B1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY | 2003-03-04 | — | — | US | disclosed |
| US-6479470-B1 | NAAG AND NAALADASE HAVE BEEN IMPLICATED IN SEVERAL PATHOLOGICAL CONDITIONS RELATING TO GLUTAMATE ABNORMALITIES AND NEUROTOXICITY | GEORGETOWN UNIVERSITY | 2002-11-12 | — | — | US | disclosed |
| WO-2000064911-A9 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | UNIV GEORGETOWN (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002022627-A2 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETWON UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1177200-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETOWN UNIVERSITY (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064911-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETOWN UNIVERSITY (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002478-A1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GRM3, GRM2, GRM1 | KIF11 2641/4885ALDH1A1 1011/4885GRIK1 15/4885 |
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GRM3, GRM2, GRM1 | KIF11 2641/4885ALDH1A1 1011/4885GRIK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.